14074 Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices 

This feature is no longer technologically 

supported. OGE proposes to discontinue 

use of the nonaccessible PDF version 

and instead add additional blank lines 

to the 508 compliant PDF version. Going 

forward, therefore, OGE seeks approval 

only for two versions of the form—the 

508 compliant PDF version and the 

Excel version. 

OMB Control Number: 3209–0006. 

Type of Information Collection: 

Extension of a currently approved 

collection. 

Type of Review Request: Regular. 

Affected public: Prospective 

Government employees, including 

special Government employees, whose 

positions are designated for confidential 

disclosure filing and whose agencies 

require that they file new entrant 

confidential disclosure reports prior to 

assuming Government responsibilities. 

Estimated Annual Number of 

Respondents: 31,654. 

Estimated Time per Response: 3 

hours. 

Estimated Total Annual Burden: 

94,962 hours. 

Request for Comments: OGE is 

publishing this first round notice of its 

intent to request paperwork clearance 

renewal for the OGE Form 450. Public 

comment is invited specifically on the 

need for and practical utility of this 

information collection, the accuracy of 

OGE’s burden estimate, the 

enhancement of quality, utility and 

clarity of the information collected, and 

the minimization of burden (including 

the use of information technology). OGE 

specifically seeks comments on whether 

the proposed changes will change the 

burden of completing the form. 

Comments received in response to this 

notice will be summarized for, and may 

be included with, the OGE request for 

extension of OMB paperwork approval. 

The comments will also become a 

matter of public record. 

Approved: February 20, 2024. 

Shelley K. Finlayson, 

Acting Director, U.S. Office of Government 

Ethics. 

[FR Doc. 2024–03813 Filed 2–23–24; 8:45 am] 

BILLING CODE 6345–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0015] 

Proposed Updates for Developing, 

Implementing, and Evaluating Infection 

Control Programs for Viral 

Hemorrhagic Fevers, Andes Virus, and 

Nipah Virus: Appendix A 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) in the 

Department of Health and Human 

Services (HHS) announces the opening 

of a docket to obtain comment on Draft 

Proposed Updates for Viral hemorrhagic 

fevers, Andes virus, and Nipah virus: 

Appendix A (‘‘Draft Updates: Appendix 

A’’). The updated recommendations in 

the Draft Updates: Appendix A are 

intended for use by frontline healthcare 

personnel, as well as infection control 

personnel and other persons responsible 

for developing, implementing, and 

evaluating infection control programs 

for healthcare settings across the 

continuum of care. 

DATES: Written comments must be 

received on or before April 26, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0015 by either of the methods listed 

below. Do not submit comments by 

email. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Healthcare Infection Control 

Practices Advisory Committee (HICPAC) 

Secretariat, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–3, Atlanta, 

Georgia 30329, Attn: Docket Number 

CDC–2024–0015. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Laura Wells, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–2, Atlanta, 

Georgia 30329; Telephone: (404) 639– 

4000. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data related to Draft Updates: Appendix 

A. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. Do not submit 

comments by email. CDC does not 

accept comment by email. 

Background 

The Draft Updates: Appendix A, 

located in the ‘‘Supporting and Related 

Material’’ tab of the docket, updates the 

recommendations in Appendix A of the 

Guideline for Isolation Precautions: 

Preventing Transmission of Infectious 

Agents in Healthcare Settings (2007) on 

the type and duration of isolation 

precautions for Viral hemorrhagic 

fevers, Andes virus, and Nipah virus. 

The Draft Updates: Appendix A 

provides recommendations to prevent 

transmission, focusing primarily on 

types and durations of precautions 

available to frontline healthcare 

personnel. The recommendations are 

being updated to include additional 

viruses with potential for importation to 

the United States. The Draft Updates: 

Appendix A is intended for use by 

frontline healthcare personnel, as well 

as infection control personnel and other 

persons responsible for developing, 

implementing, and evaluating infection 

control programs for healthcare settings 

across the continuum of care. Once the 

Draft Updates: Appendix A is finalized, 

the corresponding content in Appendix 

A of the Guideline for Isolation 

Precautions: Preventing Transmission of 

Infectious Agents in Healthcare Settings 

(2007) will be updated on the CDC 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices 14075 

Infection Control website (https://

www.cdc.gov/infectioncontrol/ 

guidelines/isolation/appendix/index.

html). 

The updated recommendations in 

Draft Updates: Appendix A are 

informed by review and consideration 

of available literature on transmission 

principles and infection prevention and 

control practices for each virus. Draft 

recommendations were presented to the 

Healthcare Infection Control Practices 

Advisory Committee (HICPAC), whose 

feedback was incorporated into the 

finalized draft recommendations. 

HICPAC is a Federal advisory 

committee appointed to provide advice 

and guidance to HHS and CDC 

regarding the practice of infection 

control and strategies for surveillance, 

prevention, and control of healthcareassociated infections, antimicrobial 

resistance, and related topics in United 

States healthcare settings. HICPAC 

includes, but is not limited to, 

representatives with expertise in public 

health, infectious diseases, and 

infection prevention and control. 

HICPAC also includes ex officio 

members who represent regulatory and 

other Federal agencies and liaison 

representatives from professional 

societies. 

CDC is seeking comments on the Draft 

Updates: Appendix A. Please provide 

references to new evidence and 

justification to support any suggested 

revisions or additions. This Draft 

Updates: Appendix A is not a Federal 

rule or regulation. 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2024–03784 Filed 2–23–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0014] 

Draft Infection Control in Healthcare 

Personnel: Epidemiology and Control 

of Selected Infections Transmitted 

Among Healthcare Personnel and 

Patients: Cytomegalovirus and 

Parvovirus B19 Sections and Draft 

Source Control Definition 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), in the 

Department of Health and Human 

Services (HHS), announces the opening 

of a docket to obtain comment on the 

Draft Infection Control in Healthcare 

Personnel: Epidemiology and Control of 

Selected Infections Transmitted Among 

Healthcare Personnel and Patients: 

Cytomegalovirus and Parvovirus B19 

Sections (‘‘Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections’’), and on the accompanying 

Draft ‘‘Source Control’’ Definition 

adapted for Infection Control in 

Healthcare Personnel to be in the 

‘‘Terminology’’ Appendix. The updated 

recommendations in the Draft 

Guideline: Cytomegalovirus and 

Parvovirus B19 Sections are intended 

for use by the leaders and staff of 

Occupational Health Services (OHS), as 

further provided herein. These updated 

recommendations will help facilitate the 

provision of occupational infection 

prevention and control services to 

healthcare personnel (HCP) who have 

been exposed or infected and may be 

contagious to others in the workplace. 

DATES: Written comments must be 

received on or before April 26, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0014 by either of the methods listed 

below. Do not submit comments by 

email. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Healthcare Infection Control 

Practices Advisory Committee (HICPAC) 

Secretariat, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–3, Atlanta, 

Georgia 30329, Attn: Docket Number 

CDC–2024–0014. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Laura Wells, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–2, Atlanta, 

Georgia 30329; Telephone: (404) 639– 

4000. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data related to the Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections, and the accompanying Draft 

‘‘Source Control’’ Definition. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. Do not submit 

comments by email. CDC does not 

accept comments by email. 

Background 

The Draft Guideline: Cytomegalovirus 

and Parvovirus B19 Sections, located in 

the ‘‘Supporting & Related Material’’ tab 

of the docket, updates the Guideline for 

infection control in health care 

personnel, 1998, Part E: Epidemiology 

and Control of Selected Infections 

Transmitted Among Health Care 

Personnel and Patients, and its 

corresponding recommendations in Part 

II of the 1998 Guideline: ‘‘3. 

Cytomegalovirus;’’ and ‘‘11. 

Parvovirus.’’ The accompanying Draft 

‘‘Source Control’’ Definition adapted for 

Infection Control in Healthcare 

Personnel to be in the ‘‘Terminology’’ 

Appendix (https://www.cdc.gov/ 

infectioncontrol/guidelines/healthcarepersonnel/terminology.html) is also 

located in the ‘‘Supporting & Related 

Material’’ tab of the docket. The 1998 

Guideline provided information and 

recommendations for Occupational 

Health Services (OHS) of healthcare 

facilities and systems on the prevention 

of transmission of infectious diseases 

among healthcare personnel (HCP) and 

patients and can be found at https://

stacks.cdc.gov/view/cdc/11563. 

As described in the Executive 

Summary of this guideline (https://

www.cdc.gov/infectioncontrol/ 

guidelines/healthcare-personnel/execsummary.html), in this document, 

‘‘OHS’’ is used synonymously with 

‘‘Employee Health,’’ ‘‘Employee Health 

Services,’’ ‘‘Employee Health and 

Safety,’’ ‘‘Occupational Health,’’ and 

other such programs. OHS refers to the 


khammond on DSKJM1Z7X2PROD with NOTICES